✦ LIBER ✦

Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: Rationale and design of phase I/II trials

✍ Scribed by François Guilhot; Martine Gardembas; Philippe Rousselot; Michel Tulliez; Magda Vigier; Agnès Buzyn; Françoise Rigal-Huguet; Laurence Legros; Mauricette Michallet; Christian Berthou; Albert Najman; Frederic Maloisel; François-Xavier Mahon; Thierry Facon; Patrice Berthaud; Joëlle Guilhot

Book ID: 117832621
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 82 KB
Volume: 40
Category: Article
ISSN: 1532-8686
DOI: 10.1053/shem.2003.50048

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 1 study of tipifarnib in combinati

Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure

✍ Jorge Cortes; Alfonso Quintás-Cardama; Guillermo Garcia-Manero; Susan O'Brien; D 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 2 views

## Abstract ## BACKGROUND. The tolerability and efficacy of the combination of tipifarnib, an orally bioavailable nonpeptidomimetic farnesyl transferase inhibitor, and imatinib was investigated in patients with chronic myelogenous leukemia in chronic phase who had failed imatinib. ## METHODS. Tw

Successful treatment of a chronic-phase

Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa

✍ Hidehiro Itonaga; Hideki Tsushima; Tomoko Hata; Emi Matsuo; Daisuke Imanishi; Yo 📂 Article 📅 2012 🏛 Carden Jennings Publishing 🌐 English ⚖ 317 KB

Results of triple therapy with interfero

Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in early chronic phase

✍ Susan O'Brien; Francis Giles; Moshe Talpaz; Jorge Cortes; Mary Beth Rios; Jianqi 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 1 views

## Abstract ## BACKGROUND Before the discovery of imatinib mesylate, a Bcr‐Abl selective tyrosine kinase inhibitor, three agents, interferon‐alpha (IFN‐α), cytarabine (ara‐C), and homoharringtonine (HHT), had demonstrated activity against Philadelphia chromosome (Ph)‐positive chronic myelogenous l

Thiotepa for the treatment of thrombocyt

Thiotepa for the treatment of thrombocythemia in patients with Philadelphia chromosome positive chronic myelogenous leukemia

✍ Edgardo J. Rodriguez-Monge; Jorge E. Cortes; Susan O'Brien; Moshe Talpaz; Hagop 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB 👁 3 views

## Background: Patients with chronic myelogenous leukemia (cml) occasionally experience persistent thrombocythemia despite having adequate white blood cell (wbc) counts. trimethylenethiophosphoramide (thiotepa) is an alkylating agent that significantly inhibits platelet production. ## Methods: Th

Phase II study of low-dose decitabine in

Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia

✍ Yasuhiro Oki; Hagop M. Kantarjian; Vazganush Gharibyan; Dan Jones; Susan O'Brien 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 161 KB 👁 2 views

Multicenter prospective trial evaluating

Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase: Does body weight matter?

✍ Yoshinobu Kanda; Shinichiro Okamoto; Tetsuzo Tauchi; Masahiro Kizaki; Koiti Inok 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 2 views

## Abstract Imatinib at a daily dose of 400 mg is the standard treatment for chronic myelogenous leukemia in the chronic phase. However, the feasibility of this dose for small Japanese adults has not been clarified. We prospectively investigated the toxicity and efficacy of this dose in adult Japan